Lasa Supergenerics
8.73
+0.09(+1.04%)
Market Cap₹43.74 Cr
PE Ratio-0.99
IndustryHealthcare
Company Performance:
1D+1.04%
1M+22.44%
6M-13.56%
1Y-50.82%
5Y-86.19%
View Company Insightsright
More news about Lasa Supergenerics
14Nov 25
Lasa Supergenerics Reports Rs 2,821.93 Crore Loss Following Devastating Factory Fire
Lasa Supergenerics Limited reported a net loss of Rs 2,821.93 crore for Q2 ending September 30, primarily due to a fire at its main manufacturing facility in May. The fire destroyed inventories and equipment worth Rs 1,973.62 crore, leading to a halt in all manufacturing operations. The company is exploring contract manufacturing and facility leasing options to resume business, subject to regulatory approvals. Auditors have highlighted the fire's impact as exceptional items in their review report.
 no imag found
22Sept 25
LASA Supergenerics' Company Secretary Resigns Citing Non-Operational Status
Mrs. Mitti Jain, Company Secretary and Compliance Officer of Lasa Supergenerics Limited, has resigned effective August 29. Her resignation letter, initially omitted but later included in a revised disclosure to stock exchanges, cites the company's non-operational status and absence of active business operations as reasons for stepping down. The resignation raises questions about Lasa Supergenerics' current operational state.
 no imag found
05Aug 25
LASA Supergenerics Bolsters Board with Four New Independent Directors
Lasa Supergenerics Limited has appointed four new Additional Directors as Non-Executive Independent Directors for a five-year term starting August 05, 2025. The new directors are Mr. Ketan Bhau Songal (Agro-Veterinary Sciences expert), Mr. Pravin Gadalya Lachake (Poultry operations specialist), Mr. Yogesh Hari Ughada (Animal care professional), and Mrs. Rekha Hemant Wakh (Animal Nutrition specialist). These appointments aim to enhance the company's leadership and bring diverse expertise in veterinary sciences, poultry operations, animal care, and nutrition to its governance structure. The appointments are subject to shareholder approval and comply with SEBI regulations.
 no imag found
Lasa Supergenerics
8.73
+0.09
(+1.04%)
1 Year Returns:-50.82%
Industry Peers
Sun Pharmaceutical
1,665.20
(-0.20%)
Divis Laboratories
6,286.00
(+0.10%)
Torrent Pharmaceuticals
4,135.70
(-1.32%)
Lupin
2,311.50
(-0.74%)
Dr Reddys Laboratories
1,220.60
(-0.97%)
Cipla
1,232.50
(+0.24%)
Zydus Life Science
928.60
(-0.84%)
Mankind Pharma
2,200.00
(+2.61%)
Aurobindo Pharma
1,391.70
(+1.75%)
Alkem Laboratories
5,696.50
(+0.97%)